 Tyvaso is being explored by United Therapeutics Corporation in the TETON program two phase 3 studies which will determine if label expansion for idiopathic pulmonary fibrosis can be achieved. Tyvaso in an ad-hoc analysis in the short 16-week INCREASE study was shown to improve FVC in PH-ILD patients with IPF. 